Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India · Delayed Price · Currency is INR | Market Cap | 81.63B +15.6% |
| Revenue (ttm) | 42.60B +6.2% |
| Net Income | 3.18B +113.2% |
| EPS | 20.78 +105.0% |
| Shares Out | 153.10M |
| PE Ratio | 25.66 |
| Forward PE | 23.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,150 |
| Average Volume | 186,275 |
| Open | 531.00 |
| Previous Close | 533.20 |
| Day's Range | 527.85 - 549.00 |
| 52-Week Range | 409.30 - 622.95 |
| Beta | n/a |
| RSI | 56.54 |
| Earnings Date | May 26, 2026 |
About NSE:AKUMS
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules f... [Read more]
Financial Performance
Financial StatementsNews
Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q3 2026 Earnings Call Highlights: Strong CDMO ...
Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q3 2026 Earnings Call Highlights: Strong CDMO Growth and Strategic Progress
Q3 2026 Akums Drugs and Pharmaceuticals Ltd Earnings Call Transcript
Q3 2026 Akums Drugs and Pharmaceuticals Ltd Earnings Call Transcript
Akums Drugs and Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw robust revenue and EBITDA growth, led by strong CDMO and international branded formulation performance, with margin expansion and improved cash flows. Key projects in Europe and Zambia are progressing, and automation initiatives are underway.
Akums Drugs shares jump over 6% after Q3 results; Revenue rises 14.8% YoY to Rs 1,160 crore
Shares of Akums Drugs and Pharmaceuticals Ltd surged more than 6% in trade after the company reported its consolidated results...
Veradermics, Incorporated IPOs Tomorrow, Here's What You Need To Know
Veradermics, Incorporated (NYSE: MANE) IPO will take place February, 04 on the NYSE exchange under the ticker MANE. The company is offering shares at an expected price between $14.00 and $16.00 per s...
Akums Drugs subsidiary faces additional Rs 1.8 crore GST penalty in Gujarat
Akums Drugs and Pharmaceuticals on Tuesday, December 16, informed stock exchanges that its wholly owned subsidiary, Maxcure Nutravedics Limited, has...
Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q2 2026 Earnings Call Highlights: Strategic ...
Akums Drugs and Pharmaceuticals Ltd (BOM:544222) Q2 2026 Earnings Call Highlights: Strategic Ventures and European Expansion Amidst Margin Pressures
Q2 2026 Akums Drugs and Pharmaceuticals Ltd Earnings Call Transcript
Q2 2026 Akums Drugs and Pharmaceuticals Ltd Earnings Call Transcript
Akums Drugs and Pharmaceuticals Transcript: Q2 25/26
Q2 FY 2026 saw a 1.5% revenue decline and a 22% EBITDA drop, mainly due to lower API prices and higher overheads, but strong cash flows and new international contracts support long-term growth. Major expansion in Zambia and Europe is expected to drive future revenue.
Akums Drugs incorporates wholly owned subsidiary in Malta, Europe
Akums Drugs and Pharmaceuticals Limited has announced the incorporation of its wholly owned subsidiary in Malta, Europe, named Akums Healthcare...
Akums Drugs and Pharmaceuticals Transcript: Q1 25/26
Revenue and profitability grew in Q1 FY26, led by CDMO and R&D milestones, despite API price declines. Cash position is strong, with a EUR 100 million EU contract advance and robust free cash flow. Mid single-digit growth is targeted for FY26, with European expansion underway.
SIMMONS FIRST NATIONAL CORPORATION ANNOUNCES PRICING OF OFFERING OF COMMON STOCK
PINE BLUFF, Ark. , July 22, 2025 /PRNewswire/ -- Simmons First National Corporation (NASDAQ: SFNC) (the "Company" or "Simmons"), parent company of Simmons Bank , today announced the pricing of its pu...
Akums Drugs and Pharmaceuticals Transcript: Q4 24/25
FY 2025 saw flat annual revenue amid API price erosion and muted volumes, but Q4 delivered double-digit growth in both revenue and EBITDA. Strong cash flows, a major European contract, and robust international expansion position the company for high single-digit volume growth and margin stability in FY 2026.
Akums Drugs and Pharmaceuticals Transcript: Q3 24/25
Secured a EUR 200 million European CDMO contract with commercial supply starting 2027 and received an upfront payment. Q3 EBITDA grew 12% year-over-year despite a 6% revenue decline, with strong CDMO margins and improved free cash flow. API losses narrowed, with break-even targeted in 1–2 years.
Akums Drugs and Pharmaceuticals shares fall over 6% following Income Tax Department search
Shares of Akums Drugs and Pharmaceuticals fell over 6% on January 22 following the company’s disclosure of an Income Tax Department search at its offices and manufacturing units. In an exchange filing...
Akums Drugs secures Rs 1,760 deal to supply oral liquid formulations in Europe
Akums Drugs and Pharmaceuticals Limited has secured a strategic agreement with a leading global pharmaceutical company for the manufacture and supply of oral liquid formulations in the European market...
Akums Drugs partners with Jagdale to revolutionize India’s Ready-to-Drink nutritional beverage market
Akums Drugs and Pharmaceuticals Ltd. has announced a strategic collaboration through its subsidiary, Maxcure Nutravedics Ltd., with Jagdale Industries Private Limited to market Ready-to-Drink (RTD) be...
Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...
Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...
Akums Drugs and Pharmaceuticals shares fall 5% following weak Q2 earnings outlook
Shares of Akums Drugs and Pharmaceuticals dropped 5% as the company reported weak Q2 earnings and projected a flat revenue outlook for the fiscal year 2024-25. The stock was trading at ₹582.10 as of 9...
Akums Drugs and Pharmaceuticals Transcript: Q2 24/25
Q2 FY25 revenue rose 2% sequentially but fell 10% YoY, impacted by lower demand and API price declines. CDMO remains the main revenue driver, while API margins stayed negative. Export expansion and new facilities are expected to support future growth.
Akums Drugs and Pharmaceuticals Q2 FY25 results: Revenue at ₹1,033.09 crore, down 12.5% YoY; profit at ₹66.65 crore, up 103.8% YoY
Akums Drugs and Pharmaceuticals Limited has released its financial results for Q2 FY25, showing mixed performance metrics. Key Financial Highlights: Revenue from Operations: For the quarter ended Sept...
Akums Drugs signs MoU with Zambian Ministry of Health to manufacture local medicine
Akums Drugs and Pharmaceuticals Limited (Akums) has signed a Memorandum of Understanding (MoU) with the Zambian Ministry of Health to manufacture local medicine. The MoU seeks to improve existing coll...
Akums Drugs shares surge 4% after company bags exclusive rights to develop Triple Hair products in India
Akums Drugs and Pharmaceuticals shares jumped more than 4% after the company announced that it received exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. The deal...
Akums Drugs secures exclusive rights to develop and market Triple Hair products in India
Akums Drugs and Pharmaceuticals has recently informed exchanges that the company has secured exclusive rights to develop and market Triple Hair Inc.’s innovative products in India. This partnership ma...